<DOC>
	<DOCNO>NCT01096862</DOCNO>
	<brief_summary>The purpose study explore efficacy safety multiple , escalate dos ASP015K compare placebo subject moderate severe plaque psoriasis .</brief_summary>
	<brief_title>A Study Explore Efficacy Safety ASP015K Subjects With Moderate Severe Psoriasis</brief_title>
	<detailed_description>Following completion least 1 week study drug subject group 1 , Sponsor review safety information subject prior enrol off-treatment subject next dose group . Dose escalation continue manner ( unless stop criterion meet ) group complete study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject moderate severe plaque psoriasis 6 month longer least 10 % Body Surface Area ( BSA ) affect Subject must candidate phototherapy and/or systemic therapy Subject nonplaque psoriasis druginduced psoriasis Subject systemic psoriasis therapy within 56 day 5 halflives , whichever longer , prior first dose study drug Subject positive TB skin test within 3 month screen screen Subject abnormal chest xray</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>ASP015K</keyword>
</DOC>